OIP	Eri
MAR 1	5 2002





SHEET \_ 1 \_ OF \_ 1

OF 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

4147-23-1 **APPLICANT** 

SERIAL NO. 10/040.572

BATHURST et al.

FILING DATE January 4, 2002

ATTY, DOCKET NO.

**GROUP ART** 1651

MAR 1 9 2001

U.S. PATENT DOCUMENTS

TECH CENTER 1600/290.

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
80)	AA	6.004,579	12/21/99	BATHURST ET AL.			
	AB	5,635,187	6/3/97	BATHURST ET AL.		_	
	AC	5.075,113	12/24/91	DUBOIS			
8	AD	4,530,788	7/23/85	CHANG			

## FOREIGN PATENT DOCUMENTS

				SUB CLASS	TRANSLATION		
DOCUMENT NUMBER	DATE	COUNTRY	CLASS		YES	ИО	

## OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

AE	Kumazawa et al., 1985. Cancer Immunology Immuntherapy, 19(2):79-84.	<b>D</b> 8
AF	Bathurst et al., 1998, Pharmaceutical Biology, 36(2):111-123.	Ш 20/00
AG		3160
		<u> </u>
		<b>M</b> Services
		C E
		AF Bathurst et al., 1998, Pharmaceutical Biology, 36(2):111-123.

EXAMINER C. R. Tate

DATE CONSIDERED 3/18/03

\*E KAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.